The public subscription window for the ₹130 crore Highway Infrastructure IPO is open today, August 5, 2025, and will close on August 7, 2025. Ahead of the IPO opening, the company had raised ₹23.4 crore from anchor investors on August 4, 2025.
Highway Infrastructure IPO is a book-building issue of ₹130 crores, consisting of a fresh issue of ₹97.52 crores and an offer for sale of ₹32.48 crores. The price band is set between ₹65 and ₹70 per share. The basis of allotment will be finalised by August 8, 2025, and the tentative listing date on BSE and NSE is August 12, 2025.
[5-August-2025, 5:00:00 PM]
Investor Category |
Subscription (Times) |
Qualified Institutional Buyers (QIBs) |
4.92 |
Non-Institutional Investors |
33.45 |
Retail Individual Investors (RIIs) |
28.69 |
Total |
27.04 |
Also Read : Highway Infrastructure IPO Allotment Status
The net proceeds from the fresh will be used to fund:
Check out newly Listed IPOs on BSE and NSE.
As of 5 August 2025, Highway Infrastructure IPO’s GMP stood at ₹40. The estimated listing price is ₹110, i.e., a 57.14% gain per share over the upper price band.
Source: Business Standard Report dated 5 August, 2025 Disclaimer: The GMP (Grey Market Premium) price is an unauthenticated market related news and has no discernible basis. The same quoted above is as per news appeared in the media report and is for information purposes only. The investor shall do their own study/research before using the same for taking any decision to invest. We neither engage in, trade, or deal in the grey market nor we recommend or endorse trading in the grey market. |
Explore other Upcoming IPOs on BSE and NSE.
Highway Infrastructure is engaged in the business of infrastructure development and operations, which includes toll collection services, EPC (Engineering, Procurement, and Construction) projects, and real estate. Among all the services provided, tollway operations are a key revenue driver for the company.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here